Utilization of antiobesity medications within the Military Health System

IF 4.2 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Obesity Pub Date : 2024-08-01 DOI:10.1002/oby.24097

Taylor Neuman, Richele Corrado, Amanda Banaag, Tracey Perez Koehlmoos

{"title":"Utilization of antiobesity medications within the Military Health System","authors":"Taylor Neuman, Richele Corrado, Amanda Banaag, Tracey Perez Koehlmoos","doi":"10.1002/oby.24097","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>The prevalence of overweight and obesity among beneficiaries of the Military Health System (MHS) is 41.6% and 30.5%, respectively. This incurs significant medical, fiscal, and military readiness costs. It is not currently known how the utilization of antiobesity medications (AOMs) within the MHS compares with that in the Veterans Health Administration or the private sector. Our aim was to assess the utilization of AOMs within the MHS.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A cross-sectional study was conducted using data gathered from the MHS Data Repository and the inclusion of all adult TRICARE Prime and Plus beneficiaries ages 18 to 64 years who were prescribed at least one TRICARE-approved AOM during the years 2018 to 2022.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The total study population included 4,414,127 beneficiaries, of whom 1,871,780 were active-duty service members. The utilization of AOMs among the eligible population was 0.56% (0.44% among active-duty personnel). Liraglutide was the most-prescribed AOM (36% of the total). Female sex, age greater than or equal to 30 but less than 60 years, and enlisted or warrant officer rank were all associated with statistically significant higher odds of receiving AOMs.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Comparable with the US private sector, the MHS significantly underutilizes AOMs, including among active-duty service members, despite coverage of AOMs since 2018.</p>\n </section>\n </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"32 10","pages":"1825-1832"},"PeriodicalIF":4.2000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.24097","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/oby.24097","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

The prevalence of overweight and obesity among beneficiaries of the Military Health System (MHS) is 41.6% and 30.5%, respectively. This incurs significant medical, fiscal, and military readiness costs. It is not currently known how the utilization of antiobesity medications (AOMs) within the MHS compares with that in the Veterans Health Administration or the private sector. Our aim was to assess the utilization of AOMs within the MHS.

Methods

A cross-sectional study was conducted using data gathered from the MHS Data Repository and the inclusion of all adult TRICARE Prime and Plus beneficiaries ages 18 to 64 years who were prescribed at least one TRICARE-approved AOM during the years 2018 to 2022.

Results

The total study population included 4,414,127 beneficiaries, of whom 1,871,780 were active-duty service members. The utilization of AOMs among the eligible population was 0.56% (0.44% among active-duty personnel). Liraglutide was the most-prescribed AOM (36% of the total). Female sex, age greater than or equal to 30 but less than 60 years, and enlisted or warrant officer rank were all associated with statistically significant higher odds of receiving AOMs.

Conclusions

Comparable with the US private sector, the MHS significantly underutilizes AOMs, including among active-duty service members, despite coverage of AOMs since 2018.

Abstract Image

查看原文本刊更多论文

军事卫生系统内抗肥胖药物的使用情况。

目的：在军队医疗系统（MHS）的受益者中，超重和肥胖的发生率分别为 41.6% 和 30.5%。这造成了巨大的医疗、财政和军事准备成本。目前尚不清楚军事卫生系统与退伍军人卫生管理局或私营部门对抗肥胖药物（AOMs）的使用情况如何比较。我们的目的是评估医疗服务系统内抗肥胖药物的使用情况：我们利用从医疗服务部数据存储库收集的数据开展了一项横断面研究，并纳入了所有年龄在 18 至 64 岁之间、在 2018 年至 2022 年期间至少开具过一种 TRICARE 批准的 AOM 的成年 TRICARE Prime 和 Plus 受益人：研究对象包括 4,414,127 名受益人，其中 1,871,780 人为现役军人。在符合条件的人群中，AOM 的使用率为 0.56%（现役军人为 0.44%）。利拉鲁肽是处方量最大的 AOM（占总数的 36%）。女性性别、年龄大于或等于 30 岁但小于 60 岁以及士兵或准尉军衔都与接受 AOMs 的几率较高有显著的统计学关联：结论：与美国私营部门相比，尽管自 2018 年起 AOMs 已被纳入医保范围，但包括现役军人在内的医疗服务系统对 AOMs 的利用率明显偏低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Obesity 医学-内分泌学与代谢

CiteScore

11.70

自引率

1.40%

发文量

261

审稿时长

2-4 weeks

期刊介绍： Obesity is the official journal of The Obesity Society and is the premier source of information for increasing knowledge, fostering translational research from basic to population science, and promoting better treatment for people with obesity. Obesity publishes important peer-reviewed research and cutting-edge reviews, commentaries, and public health and medical developments.